LifeMine Therapeutics
Cambridge Discovery Park
100 Acorn Park Drive, 6th Floor
Cambridge
Massachusetts
02140
United States
Tel: 617-945-9510
Website: http://lifeminetx.com/
14 articles about LifeMine Therapeutics
-
LifeMine Therapeutics Appoints Elliot Ehrich, M.D., as Chief Medical Officer and EVP of Translational Science and Lata Jayaraman, Ph.D., as EVP and Head of Biology
12/5/2022
LifeMine Therapeutics Inc. announced the appointment of Elliot Ehrich, M.D., as chief medical officer and executive vice president of translational science, and of Lata Jayaraman, Ph.D., as executive vice president and head of biology.
-
LifeMine Therapeutics Appoints Jennifer A. Jarrett to Board of Directors
10/13/2022
LifeMine Therapeutics Inc. today announced the appointment of Jennifer Jarrett to its board of directors.
-
Movers & Shakers: New C-Suites for Assembly Biosciences, Urica Therapeutics, BlueSphere Bio and More
10/7/2022
Life sciences and biopharma companies added new CEOs, CMOs and CSOs to guide their companies into the future and oversee developmental programs. -
LifeMine Therapeutics Expands Management Team with Appointments of Martin Stahl, Ph.D., as Chief Scientific Officer and Louis Plamondon, Ph.D., as Executive Vice President and Head of CMC
10/6/2022
LifeMine Therapeutics Inc. today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC. Dr. Stahl, former global head of lead discovery at Roche, will also lead LifeMine’s operations at its European offices in Basel, Switzerland.
-
LifeMine Therapeutics Announces $175 Million Series C Financing
3/23/2022
LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules from the biosphere, announced the completion of a $175 million Series C financing.
-
LifeMine Therapeutics and GSK Enter Drug Discovery and Development Alliance
3/23/2022
LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules from the biosphere, announced a strategic R&D collaboration with GlaxoSmithKline.
-
Read on to learn more about three Series B and C financing rounds in the areas of genetically encoded small molecules, artificial intelligence (AI) and immuno-oncology (IO).
-
BioSpace Movers & Shakers, Jan. 8
1/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
LifeMine Therapeutics Appoints Nobel Laureate William G. Kaelin Jr., M.D., to Board of Directors
1/7/2021
LifeMine Therapeutics Inc, a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced the appointment of William G. Kaelin Jr., M.D., to its board of directors. Dr. Kaelin is the Sidney Farber Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women's Hospital at Harvar
-
LifeMine Therapeutics Announces $50 Million Series B Financing
1/7/2021
Proceeds will enable advancement and acceleration of the Company’s transformative drug discovery programs derived from digital search of the fungal biosphere to discover and develop highly impactful precision medicines Significant recent scientific and operational progress includes acquisition of exquisitely biodiverse fungal strain collections amassed by Merck and Pfizer, among others, and the appointment of Nobel Laureate William G. Kaelin, Jr.,
-
LifeMine Therapeutics Powers Drug Discovery Team to Search the Biosphere for Nature's Evolved Solutions to Intractable Therapeutic Challenges
10/18/2019
LifeMine Therapeutics today announced several key appointments to its drug discovery team to include, Iain McFadyen, Ph.D., as Chief Data Officer; Jared Cumming, Ph.D., as Senior Vice President and Head of Chemistry; and Dawn Thomspon, Ph.D., as Vice President and Head of Microbiology and Automation
-
Cambridge Discovery Park Building 400-500 Will be New Headquarters for FogPharma and LifeMine Therapeutics
6/12/2019
The Bulfinch Companies, Inc. announced it has signed a 114,490 SF lease with FogPharma in building 400 at Cambridge Discovery Park.
-
BioPharm Executive: Money Talk
9/27/2017
Venture capital is hopping, attracted to some of the past several years' successes.
-
Harvard Biotech Guru, VCs Launch LifeMine With $55 Million Series A
9/20/2017